Loading...

Vicki L Wheelock

TitleProf
InstitutionUniversity of California Davis
Address
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Yuan M, Sperry L, Malhado-Chang N, Duffy A, Wheelock V, Farias S, O'Connor K, Olichney J, Shahlaie K, Zhang L. Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study. Brain Behav. 2017 Jun; 7(6):e00639. PMID: 28638698.
      View in: PubMed
    2. McGarry A, McDermott M, Kieburtz K, de Blieck EA, Beal F, Marder K, Ross C, Shoulson I, Gilbert P, Mallonee WM, Guttman M, Wojcieszek J, Kumar R, LeDoux MS, Jenkins M, Rosas HD, Nance M, Biglan K, Como P, Dubinsky RM, Shannon KM, O'Suilleabhain P, Chou K, Walker F, Martin W, Wheelock V, McCusker E, Jankovic J, Singer C, Sanchez-Ramos J, Scott B, Suchowersky O, Factor SA, Higgins DS, Molho E, Revilla F, Caviness JN, Friedman JH, Perlmutter JS, Feigin A, Anderson K, Rodriguez R, McFarland NR, Margolis RL, Farbman ES, Raymond LA, Suski V, Kostyk S, Colcher A, Seeberger L, Epping E, Esmail S, Diaz N, Fung WL, Diamond A, Frank S, Hanna P, Hermanowicz N, Dure LS, Cudkowicz M. A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology. 2017 Jan 10; 88(2):152-159. PMID: 27913695.
      View in: PubMed
    3. Fink KD, Deng P, Gutierrez J, Anderson JS, Torrest A, Komarla A, Kalomoiris S, Cary W, Anderson JD, Gruenloh W, Duffy A, Tempkin T, Annett G, Wheelock V, Segal DJ, Nolta JA. Allele-Specific Reduction of the Mutant Huntingtin Allele Using Transcription Activator-Like Effectors in Human Huntington's Disease Fibroblasts. Cell Transplant. 2016; 25(4):677-86. PMID: 26850319.
      View in: PubMed
    4. Pollock K, Dahlenburg H, Nelson H, Fink KD, Cary W, Hendrix K, Annett G, Torrest A, Deng P, Gutierrez J, Nacey C, Pepper K, Kalomoiris S, D Anderson J, McGee J, Gruenloh W, Fury B, Bauer G, Duffy A, Tempkin T, Wheelock V, Nolta JA. Human Mesenchymal Stem Cells Genetically Engineered to Overexpress Brain-derived Neurotrophic Factor Improve Outcomes in Huntington's Disease Mouse Models. Mol Ther. 2016 05; 24(5):965-77. PMID: 26765769; PMCID: PMC4881765.
    5. Fink KD, Deng P, Torrest A, Stewart H, Pollock K, Gruenloh W, Annett G, Tempkin T, Wheelock V, Nolta JA. Developing stem cell therapies for juvenile and adult-onset Huntington's disease. Regen Med. 2015; 10(5):623-46. PMID: 26237705.
      View in: PubMed
    6. Koster DP, Higginson CI, MacDougall EE, Wheelock V, Sigvardt KA. Subjective Cognitive Complaints in Parkinson Disease Without Dementia: A Preliminary Study. Appl Neuropsychol Adult. 2015; 22(4):287-92. PMID: 25495957.
      View in: PubMed
    7. Goldenholz DM, Mehra N, Dahlin B, Cohen SH, Wheelock V. Teaching neuroimages: fungus in the brain: coccidioidomycosis meningoencephalitis. Neurology. 2013 Feb 19; 80(8):e82. PMID: 23420900.
      View in: PubMed
    8. Goldenholz DM, Wong VS, Bateman LM, Apperson M, Oskarsson B, Akhtar S, Wheelock V. Treatment of ?-aminobutyric acid B receptor-antibody autoimmune encephalitis with oral corticosteroids. Arch Neurol. 2012 Aug; 69(8):1061-3. PMID: 22507884.
      View in: PubMed
    9. Olson SD, Pollock K, Kambal A, Cary W, Mitchell GM, Tempkin J, Stewart H, McGee J, Bauer G, Kim HS, Tempkin T, Wheelock V, Annett G, Dunbar G, Nolta JA. Genetically engineered mesenchymal stem cells as a proposed therapeutic for Huntington's disease. Mol Neurobiol. 2012 Feb; 45(1):87-98. PMID: 22161544; PMCID: PMC3259334.
    10. Higginson CI, Wheelock V, Levine D, Pappas CT, Sigvardt KA. Predictors of HVOT performance in Parkinson's disease. Appl Neuropsychol. 2011 Jul; 18(3):210-5. PMID: 21846220; PMCID: PMC3199217.
    11. Wong VS, Adamczyk P, Dahlin B, Richman DP, Wheelock V. Cerebral venous sinus thrombosis presenting with auditory hallucinations and illusions. Cogn Behav Neurol. 2011 Mar; 24(1):40-2. PMID: 21467920.
      View in: PubMed
    12. Higginson CI, Wheelock V, Levine D, King DS, Pappas CT, Sigvardt KA. The clinical significance of neuropsychological changes following bilateral subthalamic nucleus deep brain stimulation for Parkinson's disease. J Clin Exp Neuropsychol. 2009 Jan; 31(1):65-72. PMID: 18608676.
      View in: PubMed
    13. Higginson CI, Wheelock V, Levine D, King DS, Pappas CT, Sigvardt KA. Cognitive deficits in essential tremor consistent with frontosubcortical dysfunction. J Clin Exp Neuropsychol. 2008 Oct; 30(7):760-5. PMID: 18608666.
      View in: PubMed
    14. Higginson CI, Wheelock V, Carroll KE, Sigvardt KA. Recognition memory in Parkinson's disease with and without dementia: evidence inconsistent with the retrieval deficit hypothesis. J Clin Exp Neuropsychol. 2005 May; 27(4):516-28. PMID: 15962695.
      View in: PubMed
    15. Shook SK, Franz EA, Higginson CI, Wheelock V, Sigvardt KA. Dopamine dependency of cognitive switching and response repetition effects in Parkinson's patients. Neuropsychologia. 2005; 43(14):1990-9. PMID: 16243049.
      View in: PubMed
    16. Hurtado JM, Rubchinsky LL, Sigvardt KA, Wheelock V, Pappas CT. Temporal evolution of oscillations and synchrony in GPi/muscle pairs in Parkinson's disease. J Neurophysiol. 2005 Mar; 93(3):1569-84. PMID: 15496492.
      View in: PubMed
    17. Higginson CI, King DS, Levine D, Wheelock V, Khamphay NO, Sigvardt KA. The relationship between executive function and verbal memory in Parkinson's disease. Brain Cogn. 2003 Aug; 52(3):343-52. PMID: 12907179.
      View in: PubMed